Taking the feature that the inner layer of the peritoneum consists of EpCAM-negative mesothelial cells, anti-EpCAM antibody therapeutics have been applied to the peritoneal cavity to treat patients with peritoneal carcinomatosis (PC). Here, EPCAM is linked to pachyonychia congenita.